Last updated: July 28, 2026
How many clinical trials has praziquantel in 2024-2026 and what are the latest results
Answer: Praziquantel’s clinical-trials footprint is dominated by parasitic-disease programs (schistosomiasis, cysticercosis, and other helminthiases) and by combination and pediatric-focused studies rather than large, new monotherapy phase-development programs. Trial activity continues through investigator-led and global health sponsored studies, with most new entries targeting optimized regimens, endpoints, and delivery constraints.
Latest trial themes seen across registrations (directionally consistent over 2022-2026):
- Schistosomiasis control regimens: single-dose vs multi-day schedules, dose-ranging for children, and retreatment designs.
- Combination therapy: pairing praziquantel with other antiparasitics to improve cure rates, shorten time-to-clearance, or reduce reinfection burden.
- Pediatric and community-treatment endpoints: weight-band dosing, stool/urine conversion kinetics, and operational feasibility.
- Varying schistosome species contexts: S. mansoni vs S. haematobium; focus on egg burden reduction and urogenital outcomes.
- Diagnostic- or biomarker-driven endpoints: harmonized parasitology endpoints and, in some studies, serologic or imaging correlates.
What this means for timelines: praziquantel is already an established standard-of-care drug in schistosomiasis mass drug administration. Clinical activity now concentrates on regimen optimization and disease-ecosystem performance rather than de novo regulatory reapproval pathways.
Which praziquantel trial phases are most active
Answer: The most active trial segments are typically:
- Phase 2/2b: dose/endpoint refinement for specific populations and species.
- Phase 3: comparative regimen studies and, less frequently, head-to-head combinations.
- Phase 4 / pragmatic studies: observational and operational studies tied to control programs.
Key operational constraint shaping trial design
Praziquantel trial inclusion often depends on:
- baseline egg burden thresholds and stratification by species
- re-exposure and reinfection windows
- pediatric dosing feasibility and safety monitoring cadence
What is the praziquantel market size today and where does demand come from
Answer: Global demand for praziquantel is driven primarily by public-health procurement for schistosomiasis mass drug administration and periodic treatment campaigns. Commercial sales exist through branded and generic channels, but bulk volumes are anchored to endemic-country program cycles supported by international funders.
Primary demand drivers
- Schistosomiasis endemicity and MDA cadence
- praziquantel is used in large-scale preventative chemotherapy programs.
- Program procurement cycles
- multi-year supply agreements tied to national disease-control plans.
- Generic availability and price competition
- multiple manufacturers and local distributors reduce unit price volatility.
- Expanded elimination efforts
- continued treatment in pre- and post-elimination phases, especially where reinfection risk remains.
How pricing and procurement economics work
- Unit price pressure: generics and multiple-source supply compress margins.
- Tender-driven volume: procurement contracts typically decide winners on landed cost, packaging compliance, and lead times.
- Regulatory and quality requirements: GMP and pharmacopoeial compliance drive qualification for large procurers.
How is praziquantel expected to grow 2024-2030 and what are realistic scenarios
Answer: Growth outlook is shaped more by public-health funding cycles and endemic treatment intensity than by brand-led demand expansion. Plausible trajectories:
- Base case: low-to-mid single-digit CAGR dominated by volume durability and occasional tender-driven upswings.
- Downside: slowdowns tied to constrained public budgets, supply interruptions, or program reprioritization.
- Upside: increased coverage, intensified elimination programs, and improved detection increasing treatment eligibility.
Scenario framework for market projections
Base case drivers
- stable MDA coverage and continued use in endemic geographies
- steady replenishment cycles for multi-year plans
- moderate unit price stabilization as procurement consolidates quality-qualified suppliers
Upside drivers
- elimination-track scale-up
- improved case finding and higher treatment eligibility
- increased combination-regimen adoption where supported
Downside drivers
- funding lags at international procurement level
- supply constraints or quality rejections
- substitution in some settings by other drug regimens (where clinically and programmatically adopted)
When does praziquantel lose exclusivity and are there any patent cliffs
Answer: Praziquantel is off-patent in most major markets. Market access is largely determined by:
- generic competition
- manufacturing and quality qualification for tenders
- country-specific regulatory file ownership for generic products
Practical implication: there is no single, widely relevant “patent cliff” event for praziquantel comparable to modern specialty drugs. Market structure is already generic and procurement-based.
What still matters for market share
- product quality (bioequivalence, impurity profiles, dissolution performance)
- supply reliability and packaging compliance
- local regulatory approvals and tender eligibility
What patent estate and Orange Book listings exist for praziquantel
Answer: Praziquantel is an established, older small-molecule antiparasitic with broad generic availability. In the US, Orange Book visibility is typically limited to specific approved product dossiers and their listed patent terms, which are often expired or no longer enforceable given the drug’s age.
Commercial relevance: Orange Book listings rarely create binding barriers to additional generic market entry for praziquantel; instead, barriers are usually practical: regulatory approval status, quality standards, and tender procurement requirements.
Which companies manufacture and sell praziquantel for schistosomiasis control
Answer: The supply chain is multi-source, with global and regional generic manufacturers participating in:
- WHO and large program procurement channels (direct or via qualified distributors)
- country-level tenders and national procurement bodies
- contract manufacturing for local branded/generic products
Competitive structure:
- fragmented manufacturing base
- procurement qualification as the main gating factor
- price competition as the main commercial lever
How does praziquantel compare with other schistosomiasis drugs (oxamniquine, artemisinin, combos)
Answer: Praziquantel remains the core medicine for schistosomiasis chemotherapy in most national guidelines due to efficacy, ease of use, and established operational role.
Comparison points
- Oxamniquine: narrower geography and use in certain settings; not the dominant global choice.
- Artemisinin combinations: sometimes explored for schistosomiasis and other co-endemic conditions; not a wholesale replacement for praziquantel where praziquantel is guideline-supported.
- Combination regimens: increasing academic and program interest, but praziquantel’s baseline role typically persists.
What regulatory actions affect praziquantel availability (FDA, WHO prequalification, quality recalls)
Answer: Availability is primarily influenced by:
- generic product approvals and ongoing GMP inspections
- WHO prequalification status for program purchasing
- batch quality issues and regulatory actions that can temporarily disrupt tenders
Operational risk profile
- lower innovation risk than in newer therapeutics
- higher supply-chain and quality-compliance impact due to procurement scale
What clinical risk signals exist for praziquantel (safety, resistance, tolerability)
Answer: The safety profile is well-characterized in mass treatment contexts, with tolerability managed through dosing protocols and pediatric weight-banding.
Resistance and effectiveness considerations
- program surveillance for reduced cure rates and egg reduction is important as reinfection continues and as control programs scale.
- combination strategy exploration can reflect operational need more than evidence of widespread praziquantel resistance.
How might praziquantel market demand change with new diagnostics and elimination strategies
Answer: Elimination programs can increase long-tail demand by extending treatment beyond baseline control periods in high-risk pockets, especially where detection improves and reinfection cycles continue.
Mechanisms
- better screening identifies additional treatment-eligible individuals
- higher-resolution mapping increases local treatment frequency
- post-elimination surveillance sustains procurement at lower intensity but longer duration
Key takeaways
- Praziquantel’s clinical activity in 2024-2026 centers on regimen optimization, pediatric dosing, combination approaches, and pragmatic effectiveness endpoints rather than brand-new mechanism development.
- Market demand is primarily public-health procurement for schistosomiasis MDA; growth depends on program funding, coverage, and elimination strategy intensity more than on patent-driven exclusivity.
- Patent cliffs are not the main commercial risk. The competitive battleground is multi-source generic supply, regulatory/quality qualification, and tender economics.
- Projections 2024-2030 are best framed as scenario-based (base case stability with modest growth potential, upside tied to elimination intensification, downside tied to funding and supply disruptions).
FAQs
- Are new praziquantel combination trials likely to replace praziquantel monotherapy in schistosomiasis mass drug administration?
- What WHO procurement criteria most often determine which praziquantel generics win large tenders?
- Do praziquantel pediatric dosing studies change market demand through expanded eligibility and coverage?
- How do quality recalls or GMP actions typically affect praziquantel supply to endemic-country programs?
- What resistance or reduced-efficacy monitoring frameworks exist for schistosomiasis treated with praziquantel?
References
- World Health Organization (WHO). (n.d.). Schistosomiasis fact sheets and public health guidance. WHO.
- WHO. (n.d.). Guidelines for the treatment of schistosomiasis. WHO.
- U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA.
- ClinicalTrials.gov. (n.d.). Praziquantel clinical studies search results. National Library of Medicine.
